Prophylaxis against Recurrence in Liver Transplantation Patients with Hepatitis B Virus: What is New?

Area of Science:

• Hepatology
• Virology
• Genetics

Background:

• Hepatitis B virus (HBV) infection is a global health issue affecting nearly 2 billion people.
• HBV is a primary cause of liver cirrhosis, hepatocellular carcinoma (HCC), and liver transplantation (LT).
• Recurrence of HBV infection post-LT is a significant clinical problem driven by HBV-host genome interactions.

Purpose of the Study:

• To review the challenges and advancements in managing Hepatitis B virus recurrence after liver transplantation.
• To highlight the role of nucleoside and nucleotide analogs in preventing HBV recurrence.

Main Methods:

• Review of current literature on HBV recurrence post-LT.
• Analysis of treatment strategies, including hepatitis B immunoglobulin and antiviral nucleoside/nucleotide analogs.
• Discussion of HBV-host genome interactions influencing recurrence.

Main Results:

• Hepatitis B immunoglobulin has been a standard treatment, but resistance can occur.
• Nucleoside and nucleotide analogs, particularly those with a high genetic barrier to resistance, show promise.
• Combination therapies may offer enhanced efficacy in preventing HBV recurrence.

Conclusions:

• HBV recurrence post-LT remains a critical concern.
• Advanced nucleoside and nucleotide analogs represent powerful therapeutic options for managing HBV recurrence.
• Further research into HBV-host interactions can refine treatment strategies.